Launch a DTC Brow and Lash Serum Brand

1. 1

   Understand the cosmetic-versus-drug line before you write a word of copy

   Under FDA rules, a product's intended use is set by its claims, and a topical that claims to make hair GROW is, by that claim, a drug, which requires approval you will not have. Conditioning, nourishing, and appearance-of-fullness cosmetic claims are a different, permissible lane. The most effective growth actives, prostaglandin analogs in the bimatoprost family (the drug behind prescription Latisse), are regulated drugs with documented side effects including iris and eyelid pigmentation and orbital fat changes, and selling them over the counter as a cosmetic is a genuine compliance and safety problem. Get a regulatory-literate advisor on the copy and the formula before launch, not after a warning letter.

2. 2

   Choose your formulation lane and a compliant manufacturer

   The honest cosmetic lane is peptide-based and conditioning formulations (peptides, panthenol, biotin, castor and other oils, amino acids) that support the look and feel of brows and lashes without drug claims. Work with a cosmetic contract manufacturer that runs proper stability testing, follows good manufacturing practice, and helps with compliant labeling and safety substantiation. Never buy a random white-label serum and slap a growth claim on it. Your formula and your claims are the two things that can end the brand, so get both right at the source.

3. 3

   Build the brand, not just the bottle

   Gross margins on serum are high (often 60 to 80 percent), which means everyone can make the product, so the brand and the community are the real moat. Define a clear point of view, a name, packaging, and a founder or customer story that a specific audience recognizes as theirs. One European DTC brand reportedly reached about $988,000 in 2025 revenue with a small remote team and high margins, which is context for what a lean brand can do, not a template you will match. Decide who you are for before you decide what you charge.

4. 4

   Stand up a lean Shopify and fulfillment stack

   Shopify plus a third-party logistics partner or in-house fulfillment, a subscription app for refills, reviews, and email and SMS is the standard lean stack, and it can be run by a very small team. Price for a healthy contribution margin after cost of goods, shipping, and payment fees, because paid acquisition will eat the rest. Build the subscription path early, because a consumable that runs out monthly is a natural recurring-revenue product. Keep the operation simple until demand proves out.

5. 5

   Run the influencer and content acquisition engine

   This category is won on Instagram and TikTok through creators, user-generated before-and-afters (shown honestly and within claim limits), and paid social. Seed product to micro-influencers whose audience matches yours, use affiliate codes to make results measurable, and reinvest what works. Watch your blended customer acquisition cost against lifetime value religiously, because thin net margins mean an overpriced acquisition channel quietly bankrupts a high-gross-margin brand. Influencer dependency is the model's core risk; diversify channels as you grow.

6. 6

   Keep claims, reviews, and safety airtight as you scale

   As volume grows so does regulatory and liability exposure. Police your own marketing and your affiliates' language so no one drifts into drug claims, keep safety substantiation and adverse-event records, and honor a clear return and reaction policy. Register your facility and products as required, and keep labeling compliant as rules evolve (US cosmetic oversight tightened under recent modernization of cosmetics regulation). The brands that survive the category's growth are the ones whose compliance scaled with their revenue instead of lagging it.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

Best for: Brand builders and marketers who will respect cosmetic regulation and play the long game

Not for: Not for anyone who wants to lead with a bold growth claim, because that claim is exactly what makes the product an unapproved drug and a target. Not for founders unwilling to invest in formulation and regulatory discipline, because the category punishes shortcuts with recalls and warning letters. And not for those who need fast, effortless profit, because net margins are thin after acquisition and the real work is patient brand building.